AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
[{"orgOrder":0,"company":"Cordis","sponsor":"MedAlliance","pharmaFlowCategory":"D","amount":"$1,135.0 million","upfrontCash":"Undisclosed","newsHeadline":"Cordis Announces Acquisition of MedAlliance","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

Find Clinical Drug Pipeline Developments & Deals by Cordis

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            By acquiring MedAlliance, Cordis has the potential to serve two million patients globally by 2027 with the SELUTION SLR™ (Sustained Sirolimus Release) drug-eluting balloon for the treatment of coronary artery disease.

            Lead Product(s): Sirolimus

            Therapeutic Area: Cardiology/Vascular Diseases Product Name: Selution SLR

            Highest Development Status: Approved Product Type: Small molecule

            Recipient: MedAlliance

            Deal Size: $1,135.0 million Upfront Cash: Undisclosed

            Deal Type: Acquisition October 18, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY